Abbott Seeks FDA Approval Of A New Six-Month 45-mg Formulation Of Lupron Depot For The Palliative Treatment Of Advanced Prostate Cancer
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated [...]